Spravato vs Mindbloom: Cost, Coverage, and How Each Works

• Choose Spravato if you have insurance and a treatment-resistant depression diagnosis. You need access to a certified clinic twice a week for the first month, plus a ride home. Medicare Part B covers the visits, and commercial plans generally cover them with prior authorization.
• Choose Mindbloom if you are paying cash or have anxiety or PTSD rather than treatment-resistant depression. It may also be a better fit if regular clinic visits with two hours of monitoring are not workable. Programs cost $1,290 to $2,970, or from $215 down to $165 per session.
• Spravato is an FDA-approved esketamine nasal spray. Mindbloom prescribes compounded ketamine tablets or injections off-label, which the FDA has not evaluated for depression.

Spravato and Mindbloom take very different approaches. Spravato is Janssen’s prescription esketamine nasal spray, approved by the FDA in 2019 for treatment-resistant depression. It is given only in a clinic certified under a federal safety program, and each dose requires two hours of monitoring.

Mindbloom starts with a video screening by a psychiatrist or psychiatric nurse practitioner. A partner pharmacy then mails compounded ketamine tablets or injectables for at-home use. Another adult must be in the home during each session.

For most people, the decision comes down to diagnosis, insurance, cost, and whether regular clinic visits are realistic. Mindbloom sells 6-, 12-, or 18-session programs and does not take insurance. As of September 2026, Medicare and commercial plans pay for Spravato at the clinic. See Mindbloom’s programs or find a Spravato clinic through Janssen’s locator.

ChoosingTherapy.com may earn a commission from the companies whose services are linked on this page.

Spravato vs Mindbloom side by side

Sources, as of September 5, 2026: the Spravato FDA label, spravatorems.com, spravato.com, Mindbloom’s pricing page and help center, and the DEA’s December 2025 extension.

Choose Spravato if

• You have commercial insurance, Medicare, or Medicaid and want to use your coverage. Medicare Part B pays for Spravato visits under its own billing codes. Janssen’s withMe program can reduce the drug cost to as little as $10 per treatment for commercially insured patients.
• You have treatment-resistant depression, meaning at least two oral antidepressants have not worked. That is what Spravato is approved for and what insurers authorize.
• You prefer a drug the FDA has reviewed, supported by published placebo-controlled trials and a boxed warning you can review.
• You can reach a certified clinic twice a week for the first month, stay for two hours after each dose, and arrange a ride home. You cannot drive until the next day.
• You have depression with acute suicidal thoughts. Spravato is also approved for that use alongside an oral antidepressant. A clinician observes you for at least two hours after each dose. The label adds that Spravato has not been shown to prevent suicide or reduce suicidal thoughts.¹

Choose Mindbloom if

• You are paying cash. A 6-session program costs $1,290. Third-party estimates put one month of cash-pay Spravato induction at $4,720 to $6,785.
• You have anxiety or PTSD. Mindbloom treats both, while Spravato is not approved for either.
• Regular clinic visits are not workable. Users say rideshare costs can add up quickly when the nearest Spravato clinic is an hour away. Some describe treatment as close to unworkable without a dedicated driver.
• You live in one of Mindbloom’s 37 states or Washington, DC, and have an adult who can stay with you for an hour during each session.
• You accept off-label, compounded medication and at-home self-administration, including the risks flagged by the FDA.

What Spravato and Mindbloom cost

Mindbloom publishes its prices. New clients pay $1,290 for 6 sessions, split into three monthly installments of $430. A 12-session program costs $2,220, or $370 a month. An 18-session program costs $2,970, or $330 a month.

That works out to $215, $185 or $165 per session. The price includes medication, clinician consultations, guide coaching, the session kit and the app. Returning clients pay $954 for 6 sessions or $2,322 for 18. Tablets and injectables cost the same.

Canceling within 24 hours of the consultation carries a fee of up to $150. Once medication ships, the fee ranges from half the program price to the full price, depending on how many shipments you have received. If the clinician does not approve treatment at the consultation, Mindbloom refunds the program in full.

Janssen does not publish a Spravato price. Third-party cost guides updated in 2026 estimate the drug at about $590 for a 56 mg dose and $885 for an 84 mg dose wholesale.

CareRoute estimated an all-in cash cost of $750 to $1,100 per visit in July 2026. HealingMaps estimated $850 to $1,600 in May 2026. The clinic’s observation fee accounts for $150 to $525 of that amount. HealingMaps estimates a cash-pay induction month at $4,720 to $6,785.

Mindbloom’s pricing page claims Spravato costs “$50,000 without insurance” per year. Janssen does not make that claim, and we could not source it.

Mindbloom costs less than Spravato for anyone paying cash. Spravato costs less for a commercially insured patient using Janssen’s withMe programs. Check Mindbloom’s current program prices if you are paying cash.

Spravato insurance, Medicare, and Mindbloom reimbursement

Spravato is billed to insurance per clinic visit under codes CMS created for it in 2020. Before starting, ask whether the drug falls under your medical or pharmacy benefit and whether a local certified center is in network. CareRoute notes that “nearly all plans require prior authorization first.”²

Medicare Part B covers Spravato visits under HCPCS codes G2082 and G2083. These codes bundle the medication and the two-hour observation period. A Medicare patient’s 20 percent coinsurance runs an estimated $140 to $240 per session in 2026, after the $283 Part B deductible.³

Users describe getting Spravato approved through Medicaid after a lengthy prior authorization process. They also note that Medicaid and Medicare offer free rides to and from the clinic.

Commercially insured patients have access to two Janssen programs. The withMe Savings Program reduces the drug cost to as little as $10 per treatment. Its annual cap is set at J&J’s discretion, and third parties report it at $8,150.

The withMe Observation Rebate refunds the clinic’s monitoring fee, leaving eligible patients with a $0 observation cost after the rebate. Both programs exclude Medicare, Medicaid, TRICARE and VA patients. The observation rebate is not valid in Massachusetts, Minnesota or Rhode Island.

Mindbloom does not take insurance. Its help center lists the insurers it does not bill: Blue Cross Blue Shield, Aetna, Cigna, UnitedHealthcare, Kaiser and Anthem. Mindbloom also “does not accept Medicaid or Medicare for payment of services.”

After your first consultation, you can download a superbill for the clinician visits, billed under CPT 99204 and 99214. For a 6-session program, Mindbloom estimates “up to $650 back.” Your plan must include out-of-network coverage to reimburse any of it.

The superbill does not include the ketamine sessions, medication or guide coaching. You can pay with an HSA or FSA card, although the card processor decides what qualifies as an eligible expense.

Users repeatedly name insurance coverage as the reason they chose Spravato over an uncovered alternative.

What treatment looks like

Spravato is given in a certified clinic. Under the drug’s REMS program, “SPRAVATO must never be dispensed directly to a patient for home use.”

You administer the nasal spray yourself while a clinician watches. Your blood pressure is checked before and after the dose, and you remain at the clinic for at least two hours.

For treatment-resistant depression, the label schedule is twice a week during weeks one through four, then weekly during weeks five through eight. After that, treatment continues every one or two weeks.

The medication guide says not to drive or do anything requiring alertness “until the next day following a restful sleep.” Some users say the required two-hour stay helps them set aside time for treatment. Others find the sessions unpleasant and feel unwell for the rest of the day.

Mindbloom treatment happens at home. After a 45-minute video consultation, the medication arrives within three to six business days of approval.

The 6-session program includes two live 1:1 coaching sessions with a guide, plus messaging between sessions. The medicine sessions themselves are self-led and supervised by a peer treatment monitor.

The monitor must be an adult who stays within earshot and checks on you every 15 minutes. Mindbloom’s help center says a monitor “is required for all medicine sessions.”

The effects last about an hour. Mindbloom recommends spacing the first sessions three to seven days apart, then moving to seven to fourteen days between later sessions.

Users who switched from a year of Spravato to Mindbloom describe the injections settling into a maintenance routine. They also say the tablets can be harder to dose consistently.

Regulatory status and evidence

Spravato is FDA-approved. The January 2025 label covers treatment-resistant depression as monotherapy or alongside an oral antidepressant. It also covers depressive symptoms in major depressive disorder with acute suicidal ideation or behavior when used with an oral antidepressant.¹

The pivotal four-week trial included 223 adults. Spravato plus a new antidepressant reduced depression scores by 19.8 points, compared with 15.8 points for placebo plus an antidepressant. The FDA found the difference statistically significant.¹

In the monotherapy trial, 22.5 percent of Spravato patients reached remission at week four, compared with 7.6 percent of patients who received placebo.⁴

The label carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts. These risks are why the REMS program exists.¹

Mindbloom’s ketamine is compounded under Section 503A of federal drug law. Mindbloom’s own research page states: “Drugs compounded under Section 503A do not require FDA approval, and as such the FDA has not determined that the compounded ketamine prescribed is safe and effective for anxiety, depression, or other mental health conditions.”

The FDA’s October 2023 alert on compounded ketamine warned that “at-home administration of compounded ketamine presents additional risks because a health care provider is not available onsite to monitor for serious adverse outcomes resulting from sedation and dissociation.”⁵ Mindbloom quotes that warning on its own site.

Mindbloom’s evidence is observational. A 2024 analysis in the Journal of Affective Disorders included 11,441 Mindbloom clients, and Mindbloom staff co-authored it. The analysis reported clinically significant improvement in 62 percent of clients and remission in 28 percent after four sessions. Fewer than 5 percent reported adverse effects.⁶ The study did not include a placebo group.

Mindbloom’s comparison page places its 28 percent remission result next to an 18 percent Spravato remission figure. The Spravato number comes from a 163-patient study at three to six months. The results come from different study designs and measurement tools, so they should not be read as a head-to-head comparison.

Mindbloom’s remote prescribing model currently relies on a temporary federal rule. On December 31, 2025, the DEA extended its telemedicine flexibility through December 31, 2026.⁷

The extension allows clinicians to prescribe Schedule II to V controlled substances by video without an in-person visit. The DEA issued it to prevent what it calls the telemedicine cliff while it completes a permanent special-registration rule.

What users say

Mindbloom has a 3.9 Trustpilot score based on 808 reviews. Fifteen percent are one-star reviews, and 68 percent are five-star reviews. It has a B+ rating from the BBB without accreditation and has received 60 complaints in three years.

The five most recent Trustpilot reviews were all five stars, posted in late August and early September 2026. These reviewers praise the clinicians and describe the results as “life-changing.”

The one-star reviews from 2026 focus on shipping problems and gaps in customer support. In February, one client wrote, “Your guide will randomly depart mid-program and no one will reach out to help.” A July reviewer described a missed appointment: “They completely blew off the appointment. They didn’t cancel, they just never called.”

An April 2026 BBB complaint reported repeated refill delays of more than two weeks. Other users describe pharmacy fulfillment problems and customer support handled by an unhelpful chatbot.

Some users still stay with Mindbloom because it is the only at-home injectable ketamine option they have found and the treatment has worked for them.

Spravato does not have a Trustpilot page because it is a medication administered by independent clinics. User discussions elsewhere focus on treatment-room experiences, milestone celebrations, transportation and prior authorization. Some people who have tried both programs also describe Spravato as life-changing.

When neither Spravato nor Mindbloom fits

Ketamine in either form is not the usual next step until two antidepressants have failed you.

For people with insurance, Talkiatry offers online psychiatry in network and puts the typical patient cost at $30 per visit.

For people paying cash, Brightside charges $95 a month for its psychiatry plan, plus whatever the pharmacy charges for the prescription.

Both services prescribe conventional antidepressants only. Our Mindbloom review has more detail on the at-home experience.